Geron Corporation Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Geron Corporation announced that it granted stock options to six new employees as an inducement to employment, in accordance with Nasdaq Listing Rule 5635(c)(4). These options cover an aggregate of 311,250 shares of common stock, with an exercise price of $1.53 per share, vesting over four years. Geron is a commercial-stage biopharmaceutical company focused on blood cancer, with its drug RYTELO® approved for certain myelodysplastic syndromes.
RA Capital reports 66.5M-share Geron (GERN) position capped at 9.99% ownership
RA Capital Management, L.P. and associated entities have reported a 9.99% beneficial ownership stake in Geron Corporation (GERN) as of June 30, 2026, totaling 66,502,728 shares. This includes directly held common stock and Pre-Funded Warrants, with a "Beneficial Ownership Blocker" preventing ownership from exceeding 9.99%. The percentage calculation uses 642 million outstanding shares plus 23.7 million shares from warrant exercise, with the official SEC filing rounding down to 9.9%.
GERN|Geron Corp|Price:1.530|Chg%:-0.040
This article provides a detailed overview of Geron Corp (GERN) stock performance, financial data, and analyst ratings. It highlights the company's current stock price, market capitalization, key financial figures, and a "Buy" consensus rating from analysts with a significant upside potential. The profile section describes Geron Corp as a commercial-stage biopharmaceutical company focusing on RYTELO (imetelstat) for treating myelodysplastic syndromes.
Geron Corporation - Common Stock (NQ: GERN)
This page provides recent news headlines and financial updates for Geron Corporation (NASDAQ: GERN). Key topics include Q2 2026 earnings, RYTELO sales performance, and upcoming earnings schedules, along with stock price movements and analyst assessments. The company's RYTELO demand grew, though recent earnings reports have shown mixed results.
GERON CORP 2026: Revenue $57.48M, EPS ($0.02) — 10-Q Summary
Geron Corp (GERN) reported its 2026 quarterly results, with revenue increasing to $57.48 million and a net loss of ($16.68 million), resulting in a diluted loss per share of ($0.02). The revenue growth was primarily driven by a 17% quarter-over-quarter increase in product revenue, attributed to higher patient volume for RYTELO. The company also highlighted its U.S. commercial launch in June 2024 and EU marketing authorization in March 2025 as key developments.
State Street Corporation (GERN) discloses 5.6% beneficial stake in Geron
State Street Corporation has reported a 5.6% beneficial ownership stake in Geron Corp, holding 35,856,671 shares of common stock through its asset management subsidiaries. While State Street holds no sole voting or dispositive power, it maintains shared voting power over 34,097,965 shares and shared dispositive power over all its beneficially owned shares. This disclosure was made via a Schedule 13G SEC filing, indicating a passive investment.
Geron (NASDAQ:GERN) Posts Earnings Results, Misses Expectations By $0.01 EPS
Geron (NASDAQ:GERN) reported its quarterly earnings, missing analyst EPS expectations by $0.01 with a loss of $0.02 per share, although revenue of $57.48 million surpassed estimates. RYTELO revenue increased 17% year-over-year, and the company anticipates 2026 net product revenue to be at the mid-to-high end of its $220 million to $240 million guidance. Shares surged 21.6% despite the EPS miss and ongoing evaluation of its Phase III myelofibrosis trial.
Form 8K Geron Corporation For: 6 August By Investing.com
This article announces the filing of a Form 8K by Geron Corporation on August 6, 2026. The content is brief, primarily serving as a notification of the filing and listing the stock symbol GERN with a daily price change of -5.73%.
Form 8K Geron Corporation For: 6 August By Investing.com
This article from Investing.com announces the filing of a Form 8K by Geron Corporation for August 6. The content provides the title and date of the filing, along with the company's stock symbol and
Geron reports Q2 2026 RYTELO revenue $57.5M; net loss $16.7M; cash $327M
Geron reported Q2 2026 results, announcing RYTELO net product revenue of $57.5 million and a net loss of $16.7 million. The company ended the quarter with $326.9 million in cash and reaffirmed its full-year 2026 guidance for RYTELO revenue and operating expenses. Geron also noted sequential demand growth for RYTELO and expanded its leadership team.
[10-Q] GERON CORP Quarterly Earnings Report
Geron Corporation (GERN) has released its Q2 2026 quarterly earnings report, detailing financial performance for the period ending June 30, 2026. The report indicates that the company had $326.9 million in cash and securities, a decline from $401.1 million at the end of 2025, primarily due to net cash used in operating activities. RYTELO product revenue increased, but the company continues to incur net losses, with an accumulated deficit of approximately $1.9 billion.
GERON CORP 2026: Revenue $57.48M, EPS ($0.02) — 10-Q Summary
GERON CORP (GERN) reported its 2026 quarterly results, with revenue increasing to $57.48 million and a net loss of ($16.68 million), resulting in a diluted EPS of ($0.02). The revenue growth was primarily driven by higher patient volume for RYTELO, while the company also saw a channel shift and made progress with brand and regulatory milestones including a U.S. commercial launch and EU marketing authorization. Operational milestones include the full enrollment of Phase 3 IMpactMF and workforce reductions.
Geron earnings missed by $0.01, revenue topped estimates
Geron (NASDAQ: GERN) reported second-quarter earnings that missed analyst estimates by $0.01, with an EPS of $-0.0200 against an anticipated $-0.0100. However, the company's revenue surpassed expectations, coming in at $57.48 million compared to the consensus estimate of $55.21 million. Despite the revenue beat, Geron's stock price has seen a decline of -3.60% over both the last 3 months and the last 12 months.
Geron Releases Q2 2026 Financial Results
Geron Corporation reported a wider-than-expected loss for Q2 2026, with a net loss per share of -$0.02, exceeding the -$0.01 estimate. Despite the loss, the company's oncology therapeutic RYTELO generated $57.5 million in revenue, surpassing estimates and showing significant year-over-year growth. Geron also provided full-year revenue guidance of $220.0 million to $240.0 million.
Geron stock gains after Q2 revenue beat (GERN:NASDAQ)
Geron (GERN) stock gained 16% after the company reported Q2 2026 revenue that exceeded Street forecasts. This strong performance was driven by sales of its blood cancer therapy, Rytelo. The surge marks Geron's best single-day gain in over two years.
Geron (GERN) Reports Q2 Loss, Beats Revenue Estimates
Geron (GERN) reported a Q2 loss of $0.02 per share, which missed the Zacks Consensus Estimate of a $0.01 loss. However, the company surpassed revenue expectations, posting $57.48 million against an estimate of $55.01 million. Despite the revenue beat, the stock holds a Zacks Rank #4 (Sell) due to unfavorable estimate revisions, suggesting potential underperformance in the near future.
Earnings Flash (GERN) Geron Corporation Reports Q2 Revenue $57.5M, vs. FactSet Est of $55.3M
Geron Corporation announced Q2 revenue of $57.5 million, surpassing the FactSet estimate of $55.3 million. The company also provided earnings guidance for 2026 and reported earnings results for the second quarter and six months ended June 30, 2026. Geron is a commercial-stage biopharmaceutical company focused on developing its telomerase inhibitor, RYTELO, for various myeloid hematologic malignancies.
Geron Corporation Reports Second Quarter 2026 Financial Results and Recent Business Highlights
Geron Corporation announced its second quarter 2026 financial results, reporting $57.5 million in RYTELO net product revenue, an 11% increase from Q1 2026. The company reiterated its 2026 guidance for RYTELO net product revenue to be between $220 million and $240 million, and total operating expenses between $230 million and $240 million. Geron ended the quarter with $327 million in cash and marketable securities and highlighted continued demand growth for RYTELO in the U.S. and advancements in its clinical trials.
Earnings Preview: Geron to Report Financial Results Pre-market on August 05
Geron Corporation (GERN) is scheduled to release its financial results on August 5, 2026, before the market opens. Analysts forecast an EPS of -$0.04 and revenue of $4 million for the quarter. Investors will be keenly watching these results to gauge the company's financial health and future prospects.
Geron Corp (GERN) Valuation: PE, PB & Fair Value Analysis
Geron Corp (GERN) currently holds a valuation score of 7.81, placing it 191st out of 384 companies in the Biotechnology & Medical Research industry. The article highlights its P/E ratio of -13.88, which is a significant drop from its recent high, while noting that relevant P/B, P/S, and P/CF data are not yet disclosed by the company. The analysis provides key financial figures and market capitalization for GERN.
Geron Market Sentiment
This article provides an overview of market sentiment for Geron (GERN), highlighting analyst consensus, short interest, options flow, and recent insider activity. Key signals show a "Buy" analyst consensus, 12.5% rising short interest, and a bullish options flow with a 0.01 P/C ratio. The article also lists recent analyst ratings, price target changes, and related news, such as whale activity and insider stock acquisitions.
Geron Corp (GERN) Financial Health: Profitability & Balance Sheet Analysis
Geron Corp (GERN) has a current financial score of 8.58, ranking 41 out of 385 in the Biotechnology & Medical Research industry, indicating a weak financial status but high operating efficiency. The company's latest quarterly revenue saw a 30.89% year-over-year increase, reaching $51.84M, while its net profit increased by 81.64% year-over-year. Key detailed financial data for aspects like cash and cash equivalents, total assets, total liabilities, and free cash flow have not been disclosed yet.
Geron Corp (GERN) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution
This article from TradingKey attempts to provide a revenue breakdown for Geron Corp (GERN) by business segments and regional contributions. However, the site states that relevant financial data for these categories have not yet been disclosed by the company. Consequently, no specific revenue figures or breakdowns are presented.
GERN|Geron Corp|Price:1.415|Chg%:-0.035
This article provides a comprehensive stock analysis of Geron Corp (GERN) by TradingKey, highlighting its stable fundamentals, high growth potential, and fair valuation within the Biotechnology & Medical Research industry. Despite positive analyst ratings and recent market outperformance, technical indicators suggest the stock is trading sideways. The analysis details key insights such as high institutional ownership, accelerated revenue growth, and specific strengths and risks related to its biopharmaceutical pipeline.
Geron Corp (GERN) Cash Flow
This article provides a detailed historical cash flow statement for Geron Corp (GERN), covering quarterly and annual data for operating, investing, and financing activities. It breaks down various components of cash flow and offers definitions for key financial metrics like operating cash flow, investing cash flow, financing cash flow, and free cash flow. The data highlights Geron Corp's past cash flow performance and changes year-over-year.
Geron Corp (GERN) Shareholder Structure: Major Shareholders & Institutional Holdings
This article details the shareholder structure of Geron Corp (GERN), listing major shareholders and their proportional holdings, along with a breakdown by shareholder type. It also provides a historical overview of institutional shareholding data and recent shareholder activity, including changes in holdings by key investors, and lists related ETFs that include GERN.
TradingKey
This page provides a detailed quarterly and annual income statement for Geron Corp (GERN), allowing users to analyze the company's financial performance and operational efficiency. It presents various financial metrics including revenue, operating expenses, net income, and earnings per share, along with year-over-year comparisons. The page also includes an FAQ section explaining how to read the income statement and defining key financial terms.
Geron Corp (GERN) Institutional Confidence
Geron Corp (GERN) has an institutional shareholding score of 7.00, placing it 80th in the Biotechnology & Medical Research industry. The latest institutional shareholding proportion is 76.90%, showing a quarter-over-quarter decrease of 5.14%. Steven Cohen is the largest institutional shareholder, holding 3.19% of the outstanding shares.
Geron Corporation Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Geron Corporation announced inducement grants of stock options to five new employees. These grants, totaling 202,500 shares of common stock, were made effective July 17, 2026, with an exercise price of $1.44 per share and a ten-year term, vesting over four years. The grants comply with Nasdaq Listing Rule 5635(c)(4) and aim to incentivize the employees' acceptance of employment.
Five New Geron Hires Receive Options at $1.44 Per Share
Geron (Nasdaq: GERN) has granted stock options for a total of 202,500 common shares to five new employees, effective July 17, 2026, as an inducement for their employment. The options have an exercise price of $1.44 per share, matching the closing price on the grant date, and come with a ten-year term and a four-year vesting schedule. This action aligns with Nasdaq Listing Rule 5635(c)(4) and Geron's 2018 Inducement Award Plan.
Geron Corporation Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Geron Corporation announced that it granted stock options to five new employees as an inducement to employment, in accordance with Nasdaq Listing Rule 5635(c)(4). These options cover 202,500 shares of common stock, with an exercise price of $1.44 per share, vesting over four years. Geron is a commercial-stage biopharmaceutical company focusing on blood cancer treatments.
Geron Schedules 8 a.m. Q2 Conference Call for Aug. 5
Geron (Nasdaq: GERN) announced it will report its second quarter 2026 financial results and business highlights before market open on August 5, 2026. The biopharmaceutical company will also host a conference call and webcast at 8:00 a.m. Eastern Time via its website's Investors and Media section. This announcement provides timing for the upcoming earnings release, with previous earnings-date notices showing mixed stock reactions.
Geron Plans to Announce Second Quarter 2026 Financial Results on August 5, 2026
Geron Corporation announced it will release its second quarter 2026 financial results and business highlights on Wednesday, August 5, 2026, before the market opens. The company will also host a conference call and webcast at 8:00 a.m. Eastern Time. Geron is a commercial-stage biopharmaceutical company focused on blood cancer treatments, including its approved telomerase inhibitor RYTELO® (imetelstat).
Geron Plans to Announce Second Quarter 2026 Financial Results on August 5, 2026
Geron Corporation announced it will release its second quarter 2026 financial results and business highlights on Wednesday, August 5, 2026, before market open. The company will also host a conference call and webcast at 8:00 a.m. Eastern Time to discuss the results and provide business updates. Geron focuses on developing treatments for blood cancers, with its telomerase inhibitor RYTELO® (imetelstat) already approved for certain myelodysplastic syndromes.
Geron Corporation Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Geron Corporation announced an inducement grant of a stock option to purchase 1,700,000 shares of common stock to Chinmaya Rath, the company's new Chief Business Officer. The grant was material to his acceptance of employment and was approved by the Compensation Committee in accordance with Nasdaq Listing Rule 5635(c)(4). The stock option has an exercise price of $1.42 per share, a ten-year term, and vests over four years.
Geron Corporation Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Geron Corporation announced an inducement grant in the form of a stock option to purchase 1,700,000 shares of its common stock for Chinmaya Rath, the new Chief Business Officer. The grant, made on July 13, 2026, has an exercise price of $1.42 per share and vests over four years, in compliance with Nasdaq Listing Rule 5635(c)(4). Geron is a biopharmaceutical company focused on blood cancer treatments, with its drug RYTELO® (imetelstat) approved for certain myelodysplastic syndromes.
Geron's New Business Chief Gets Option on 1.7M Shares
Geron (GERN) granted a stock option to its new Chief Business Officer, Chinmaya Rath, entitling him to purchase 1.7 million shares of common stock. This inducement award, detailed in a recent report, has an exercise price of $1.42 per share, matching the closing price on the grant date of July 13, 2026. The option vests over four years, with an initial 12.5% after six months and the remainder in equal monthly installments for the subsequent 42 months, subject to his continued employment.
Geron Corporation Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Geron Corporation announced an inducement equity award to Chinmaya Rath, their new Chief Business Officer. The grant includes a stock option to purchase 1,700,000 shares of Geron common stock at an exercise price of $1.42 per share, vesting over four years. This grant was approved by the Compensation Committee in accordance with Nasdaq Listing Rule 5635(c)(4).
Veteran dealmaker from Novartis and Cellworks joins Geron to steer RYTELO growth
Geron (Nasdaq: GERN) has appointed Chinmaya Rath as its new Chief Business Officer, effective July 13, 2026. Rath brings over 25 years of biopharma leadership experience from companies like Novartis and Cellworks, and will focus on maximizing RYTELO's global value and expanding Geron's hematology business. His expertise includes oncology launches and strategic integrations, which Geron believes will drive continued growth and operational excellence.
Geron appoints Chinmaya Rath as chief business officer
Geron Corporation has appointed Chinmaya Rath as Chief Business Officer, leveraging his 25 years of biopharmaceutical leadership experience from companies like Novartis and Cellworks. Rath will contribute to the commercial-stage company, which markets RYTELO for myelodysplastic syndromes and is conducting a Phase 3 trial for myelofibrosis. The company recently reported strong financial results for Q1 2026, exceeding revenue forecasts and achieving a smaller-than-expected loss per share.
Geron Announces Appointment of Chinmaya Rath as Chief Business Officer
Geron Corporation has appointed Chinmaya Rath as its new Chief Business Officer. Rath brings over 25 years of biopharmaceutical leadership experience and will focus on maximizing the value of Geron's drug RYTELO and exploring new opportunities to expand the company's hematology presence. His appointment aims to strengthen Geron's strategic execution and accelerate its growth in the blood cancer treatment market.
Geron Announces Appointment of Chinmaya Rath as Chief Business Officer
Geron Corporation announced the appointment of Chinmaya Rath as Chief Business Officer, effective July 13, 2026. Rath brings over 25 years of biopharma leadership experience, including significant roles at Novartis, and will focus on maximizing RYTELO's value and evaluating innovation to build a leading hematology company. His appointment aims to strengthen Geron's strategic insights and executional focus as it continues commercializing RYTELO for blood cancers.
ETFs Investing in Geron Corporation Stocks
This article provides a comprehensive list of Exchange Traded Funds (ETFs) that hold shares of Geron Corporation (0IV3 on the London Stock Exchange). It details various ETFs, including their market value, weight of Geron stock, issuer, management style, expense ratio, assets under management (AUM), and 3-year NAV total return. The ETFs cover diverse categories such as biotechnology, small-cap, and health care, offering investors different avenues to gain exposure to Geron Corporation.
Geron stock leans on its myelofibrosis story
Geron's stock performance is closely linked to the commercial rollout of its lead product, Rytelo, for myelofibrosis. The biotechnology company, listed on Nasdaq, focuses on blood-cancer therapies, with execution in sales adoption and physician uptake being crucial for its market sentiment. Rytelo targets a specialized patient population, making clinical positioning and reimbursement key to revenue growth.
Form 4 Geron Corporation For: 1 July By Investing.com
This article from Investing.com announces the filing of a Form 4 for Geron Corporation on July 1st. Form 4 is a document that must be filed with the U.S. Securities and Exchange Commission (SEC) by company insiders (officers, directors, or beneficial owners of more than 10% of a class of the company's equity securities) whenever they trade shares in their own company. The article provides current market data for various indices, commodities, and stocks.
Geron (GERN) director Robert J. Spiegel receives 6,103-share stock grant for board fees
Geron Corp. (GERN) director Robert J. Spiegel received a grant of 6,103 shares of common stock on June 30, 2026, as compensation for his quarterly board retainer and committee fees. The shares were valued at $1.28 each, based on the closing price of the company's stock that day. Following this transaction, Spiegel directly holds 205,810 Geron common shares, a routine compensation award rather than an open-market purchase.
GERN Forecast — Price Target — Prediction for 2027
This article provides a forecast and price target for Geron Corporation (GERN) stock, indicating current stock performance, analyst opinions, and key financial metrics. It highlights GERN's present stock price, recent percentage changes, historical highs and lows, and upcoming earnings report date. The company's market capitalization, volatility, and employment figures are also discussed.
GERN Stock Steadies As Geron Builds Commercial Momentum
Geron Corporation (GERN) stock is experiencing a 7.14% increase due to positive sentiment surrounding its late-stage blood cancer therapy. The company has granted significant stock options to new employees, signaling aggressive talent acquisition, and is demonstrating commercial momentum with its approved RYTELO therapy and an ongoing Phase 3 trial. While revenue is rising, the company still faces negative profits and cash burn, positioning it as a catalyst-driven stock for traders.
Geron Corporation Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Geron Corporation announced inducement grants of stock options to eight new employees, as specified under Nasdaq Listing Rule 5635(c)(4). These grants, totaling 690,000 shares, have an exercise price of $1.23 per share and a ten-year term, vesting over four years. Geron is a commercial-stage biopharmaceutical company focused on blood cancer treatments, with its drug RYTELO® approved for certain myelodysplastic syndromes.
Geron Corporation Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Geron Corporation announced the grant of stock options to eight new employees as an inducement for their employment. These options, totaling 690,000 shares, have an exercise price of $1.23 per share and a ten-year term, vesting over four years. This action is in accordance with Nasdaq Listing Rule 5635(c)(4) and aims to attract new talent to the biopharmaceutical company.
